Oppenheimer initiated coverage on Acasti Pharma with a new price target
$ACST
Biotechnology: Pharmaceutical Preparations
Health Care
Oppenheimer initiated coverage of Acasti Pharma with a rating of Outperform and set a new price target of $6.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/22/2021 | $6.00 | Outperform | Oppenheimer |
| 12/21/2021 | $6.00 | Outperform | Oppenheimer |
4 - Acasti Pharma Inc. (0001444192) (Issuer)